Array BioPharma Inc. (ARRY)

Oncology Corporate Profile

Stock Performance


3 Month Stock History Chart

Data provided for free by IEX.

HQ Location

3200 Walnut Street
Boulder, CO 80301

Company Description

Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat debilitating and life-threatening diseases. Array's proprietary drug development pipeline is primarily focused on the treatment of cancer and inflammatory disease and includes clinical candidates that are designed to regulate therapeutically important targets.


This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
LGX818RAF kinase inhibitor1st line metastatic MelanomaIII
MEK162MEK inhibitor1st line metastatic MelanomaIII
selumetinib / AZD6244 (ARRY-886)MEK inhibitor1st line metastatic MelanomaIIAstraZeneca
ARRY-520KSP inhibitor2nd line metastatic Multiple MyelomaII
selumetinib / AZD6244 (ARRY-886)MEK inhibitor2nd line metastatic Non Small Cell Lung cancer (NSCLC)IIAstraZeneca
filanesib / ARRY-520KSP inhibitor3rd line metastatic Multiple MyelomaII
ipatasertib / GDC-0068AKT inhibitorBreast cancerII
ARRY-543pan-HER inhibitorGastric cancerIIASLAN
motolimod / VTX2337toll-like receptor 8 agonistVarious cancer typesIIVentiRx/Celgen
ipatasertib / GDC-0068AKT inhibitorVarious cancer typesIIGenentech / Roche
filanesib / ARRY-520KSP inhibitorAcute Myelogenous Leukemia (AML)I
ARRY-380ErbB-2 inhibitorBreast cancerI
binimetinib (+ pembrolizumab)MEK inhibitorColorectal cancerIMerck
ARRY-614p38/Tie-2 inhibitorVarious cancer typesI
LY2606368Chk-1 inhibitorVarious cancer typesIEli Lilly
GDC-0994ERK inhibitorVarious cancer typesIGenentech / Roche
LOXO-101TRK inhibitorVarious cancer typesILOXO
ARRY-543ErbB-2 and EGFR dual kinase inhibitorVarious cancer typesI
ARRY-380ErbB-2 inhibitorVarious cancer typesI
filanesib / ARRY-520KSP inhibitorVarious cancer typesI

View additional information on product candidates here »


Recent News Headlines

Array BioPharma and Pierre Fabre Announce COLUMBUS Phase 3 Study of Encorafenib plus Binimetinib For BRAF-Mutant Melanoma Met Primary Endpoint

9/26/2016 05:09 pm

(The Business Journals) Sept 26, 2016 - Demonstrated statistically significant results with median PFS on combination of encorafenib plus binimetinib 14.9 months versus 7.3 months on vemurafenib.

Array BioPharma Announces Phase 3 BEACON CRC SPA Agreement with FDA

9/14/2016 04:38 pm

(Yahoo! Finance) Sept 14, 2016 - Array BioPharma announced today that it has reached agreement with the FDA regarding a Special Protocol Assessment (SPA) related to BEACON CRC, a global Phase 3 trial of encorafenib and Erbitux® (cetuximab), with or without binimetinib, versus standard of care in patients with BRAF-mutant colorectal cancer (CRC) who have previously received first-or second-line systemic therapy.

Array BioPharma Announces FDA Acceptance of Binimetinib NDA for Patients with Advanced NRAS-Mutant Melanoma

9/1/2016 04:14 pm

(The Business Journal) Sept 1, 2016 - Array BioPharma today announced that the FDA has accepted its New Drug Application (NDA) for binimetinib with a target action date under the Prescription Drug User Fee Act (PDUFA) of June 30, 2017.

Array BioPharma Submits Binimetinib New Drug Application to U.S. FDA

7/1/2016 02:55 pm

(Yahoo! Finance) June 30, 2016 - Array BioPharma today announced the submission of a New Drug Application (NDA) for binimetinib in patients with advanced NRAS-mutant melanoma to the U.S. Food and Drug Administration (FDA).

Array Presents Full Results From Phase 3 NEMO Study

6/6/2016 10:19 pm

(Array BioPharma) June 6, 2016 - Binimetinib meets primary PFS endpoint in high unmet need patient population.

Array BioPharma, Pierre Fabre and Merck KGaA, Darmstadt, Germany Announce Phase 3 BEACON CRC Trial

6/4/2016 10:41 pm

(Yahoo! Finance) June 4, 2016 - Global partnership to conduct randomized, Phase 3 trial evaluating safety and efficacy of binimetinib, encorafenib and Erbitux® (cetuximab) in BRAF-mutant colorectal cancer.

Peregrine Pharmaceuticals Provides Corporate Update Highlighting Latest Developments for Contract Manufacturing and Drug Development Businesses

6/2/2016 12:02 pm

(NASDAQ) June 2, 2016 - Drug development strategy to focus on early stage clinical trials of bavituximab and immuno-oncology (I-O) combinations.

Flatiron Health and the FDA Embark on Cancer Research Collaboration

5/25/2016 11:01 am

(Flatiron Health) May 25, 2016 - Flatiron Health and the U.S. Food and Drug Administration (FDA) have signed a research collaboration agreement to determine how real-world evidence derived from de-identified, HIPAA-compliant patient data captured outside of clinical trials can provide new insights into the safety and effectiveness of emerging anti-cancer therapies such as immunotherapeutic agents.

Array BioPharma Announces Key Data From NRAS-mutant Melanoma and BRAF-mutant Colorectal Cancer ASCO 2016 Presentations

5/19/2016 05:30 pm

(Array BioPharma) May 18, 2016 - Array BioPharma will present additional data on its late-stage candidates binimetinib and encorafenib in NRAS-mutant melanoma and BRAF-mutant colorectal cancer, respectively, at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois on June 3 - 7.

Considerations for Designing "Value Calculators" for Oncology Therapies

5/13/2016 11:04 am

(AJMC) May 12, 2016 - A review of the various value calculators that have emerged to measure the value of cancer therapies—these calculators reflect the interests of their developers and vary substantially in their intention, format, and usability.

CMS Requests Doc Input on MACRA

5/5/2016 11:05 am

(Modern Healthcare) May 4, 2016 - CMS Acting Administrator Andy Slavitt struck a strongly conciliatory tone Wednesday at the second meeting of the committee created to evaluate payment models to be used in Medicare's new reimbursement for physicians.

Tennessee Oncology Selected for Oncology Care Model

4/18/2016 12:00 pm

(Tennessee Oncology) Apr 14, 2016 - Tennessee Oncology has been selected to participate in the Centers for Medicare and Medicaid Services Oncology Care Model for a five-year period, beginning July 1.

Array BioPharma Announces Decision To Discontinue MILO Study In Ovarian Cancer

4/1/2016 01:10 pm

(Array BioPharma) Apr 1, 2016 - Array BioPharma Inc. announced today its decision to discontinue the MILO study, a Phase 3 trial of binimetinib for the treatment of patients with low-grade serous ovarian cancer.

Halozyme Doses First Patient In Phase 3 Clinical Trial Of PEGPH20 In Combination With ABRAXANE® And Gemcitabine

3/16/2016 11:05 am

(4-traders) Mar 16, 2016 - Halozyme Therapeutics, Inc., a biotechnology company developing novel oncology and drug-delivery therapies, today announced the first patient has been dosed in its Halo-301 | Pancreatic study, a Phase 3 clinical trial in previously untreated metastatic pancreatic cancer patients.

IBM to Buy Truven Health Analytics for $2.6 Billion

2/18/2016 12:04 pm

(Wall Street Journal) Feb 18, 2016 - IBM will use Truven’s trove of medical data to improve its Watson artificial-intelligence system.

F.D.A. Deals Setback to Catalyst in Race for Drug Approval

2/18/2016 12:04 pm

(New York Times) Feb 17, 2016 - Catalyst Pharmaceuticals, vying for exclusive rights to a drug that treats a rare neuromuscular condition, received a letter saying its application was incomplete.

Injuries and Other Health Concerns Are More Common In Older People After Certain Cancer Surgeries

2/17/2016 11:05 am

(UCLA) Feb 16, 2016 - Older people who undergo cancer surgery are more likely than their younger counterparts to experience injuries and health issues such as falling down, breaking bones, dehydration, bed sores, failure to thrive and delirium.

Miami Cancer Institute at Baptist Health South Florida Joins Memorial Sloan Kettering Cancer Alliance

2/10/2016 11:04 am

(MSK) Feb 10, 2016 - Memorial Sloan Kettering Cancer Center (MSK) and Miami Cancer Institute at Baptist Health South Florida announce the beginning of a dynamic and forward-thinking collaboration aimed at improving patient access to the latest and most effective cancer treatment advances and the highest caliber of cancer care.

Dana-Farber Cancer Institute's Belfer Center Announces Immuno-Oncology Research Collaboration with Array BioPharma

2/1/2016 05:43 pm

(Array BioPharma) Feb 1, 2016 - Dana-Farber Cancer Institute today announced an immuno-oncology collaboration with potential applicability in a wide range of oncology indications with Array BioPharma.

Array BioPharma Cancer Drug Succeeds In Late-Stage Study

12/16/2015 06:57 pm

(Reuters) Dec 16, 2015 - Array BioPharma Inc said its experimental drug helped patients with a form of melanoma live longer without their cancer progressing, in an ongoing late-stage study.

Array BioPharma Announces Phase 3 Binimetinib Trial Meets Primary Endpoint For NRAS-Mutant Melanoma

12/16/2015 01:18 pm

(Array BioPharma) Dec 16, 2015 - Array BioPharma today reported top-line results from the ongoing Phase 3 clinical trial of binimetinib in patients with advanced NRAS-mutant melanoma, known as the NEMO trial.

BioLight, Axella to Advance CellDetect In Bladder Cancer

11/30/2015 12:01 pm

(BioTuesdays) Nov 30, 2015 - BioLight Life Sciences Investments’ cancer diagnostics subsidiary, Micromedic Technologies, has entered into a collaboration agreement with Axella Research to advance the clinical and regulatory requirements to commercialize BioLight’s CellDetect non-invasive diagnostic test for monitoring bladder cancer recurrence in the U.S.

What Hematologists Need to Know about the Medicare Merit-based Incentive Payment System

11/30/2015 12:01 pm

(ASH) Nov 24, 2015 - Good to understand MACRA – but don’t panic (Part 1).

The American Society of Hematology and McMaster University Announce Partnership to Develop Clinical Practice Guidelines on Venous Thromboembolism

11/30/2015 12:01 pm

(ASH) Nov 30, 2015 - Guidelines on the treatment and diagnosis of VTE anticipated In 2017.

Informal Review Requests of the 2016 Value Modifier Due to CMS by Dec. 16

11/30/2015 12:01 pm

(ASCO in Action) Nov 25, 2015 - The Centers for Medicare & Medicaid Services is currently accepting informal requests to review the 2016 Value Modifier.

Deadline to Check on PQRS Incentive Payments Further Extended to Dec. 16

11/30/2015 12:01 pm

(ASCO in Action) Nov 25, 2015 - For a second time, the Centers for Medicare & Medicaid Services (CMS) has extended the deadline for eligible individuals and groups that believe they have been incorrectly identified for the 2016 Physician Quality Reporting System (PQRS) negative payment adjustment to submit an informal review request.

Five Key Issues For Future Cancer Care And Health Informatics

11/30/2015 12:01 pm

(Forbes) Nov 30, 2015 - Oncology IT will harness information from millions of cancer patients, now and in years ahead, connect the dots, and – as new medications arrive from the pipeline – nudge doctors and patients toward optimal treatments.

Major Shareholder Wants Inquiry Into Northwest Biotherapeutics Allegations

11/30/2015 12:01 pm

(Wall Street Journal) Nov 28, 2015 - A major shareholder is urging biotechnology firm Northwest Biotherapeutics to hold an inquiry into allegations about the governance of the company by Chairwoman and Chief Executive Linda Powers.

Conditional EU Nod For Amgen's Rare Leukemia Drug

11/30/2015 12:00 pm

(PharmaTimes [UK]) Nov 24, 2015 - Amgen’s cancer immunotherapy Blincyto has won conditional approval in Europe for the treatment of a rare type of leukaemia.

Draft Guidance For Recurrent Ovarian Cancer

11/30/2015 12:00 pm

(The Pharmaceutical Journal [UK]) Nov 30, 2015 - The National Institute for Health and Care Excellence (NICE) has published draft guidance that covers five drugs — paclitaxel, pegylated liposomal doxorubicin hydrochloride (PLDH), topotecan, trabectedin and gemcitabine — for treating recurrent ovarian cancer.

Clinigen Will Manage Programme For New Blood Cancer Drug

11/30/2015 12:00 pm

(Proactive Investors) Nov 30, 2015 - Clinigen said it will oversee the managed access programme for Takeda Pharmaceutical’s ixazomib that treats the blood cancer multiple myeloma.

NCCN Collaborates With Bristol-Myers Squibb to Study PD-L1 Expression and Test Interpretation in Lung Cancer

11/30/2015 12:00 pm

(NCCN) Nov 30, 2015 - NCCN is collaborating with Bristol-Myers Squibb to promote the advancement of scientific knowledge concerning programmed death-ligand 1 (PD-L1) protein expression and other immune markers in lung cancer.

Ignyta and EORTC Announce Entrectinib Selected as First Investigational Cancer Agent to be Included in EORTC SPECTA Precision Medicine Clinical Trial Program

11/30/2015 12:00 pm

(Yahoo! Finance) Nov 30, 2015 - Ignyta, Inc., a precision oncology biotechnology company, and the European Organisation for Research and Treatment of Cancer (EORTC) today announced that they will collaborate via EORTC’s Screening Patients for Efficient Clinical Trial Access (SPECTA) biomarker screening initiative to identify patients who harbor a gene rearrangement to NTRK1, NTRK3, ROS1 or ALK and therefore may be eligible for Ignyta’s global STARTRK-2 Phase 2 clinical study.

Aetna Expert Explores New Cancer Payment Methodology

11/30/2015 12:00 pm

(Managed Healthcare Executive) Nov 29, 2015 - New payment models that were initially developed for primary care or common surgical procedures are now being developed and used for patients with blood diseases.

FDA Clears Siemens CT Scanners for Low-Dose Lung Cancer Screening

11/30/2015 12:00 pm

(Siemens USA) Nov 30, 2015 - The Food and Drug Administration (FDA) has cleared Siemens Healthcare’s SOMATOM computed tomography (CT) systems for low-dose lung cancer screening.

Exact Sciences Addresses CMS’s 2016 Clinical Diagnostic Laboratory Fee Schedule

11/30/2015 12:00 pm

(Exact Sciences) Nov 27, 2015 - On November 25, 2015, the Centers for Medicare and Medicaid Services (CMS) posted the 2016 Clinical Diagnostic Laboratory Fee Schedule (CLFS) on its website.